

TOP TEN DRUGMAKERS OF 2024 BASED ON PROJECTED SALES

In 2024, the top ten drugmakers will generate more than \$420 billion in sales, holding some 35% of the biopharma market share, according to a recent report from EvaluatePharma. The leading companies will continue to compete to increase their sales in both established and emerging therapeutic areas, with particular attention paid to cancer and immunology. Though there may be some changes due to mergers, the report listed the following companies as likely to be in the top ten.

#1 NOVARTIS

Headquarters: Basel, Switzerland
2017 prescription sales: \$41.9 billion
Projected 2024 sales: \$53.2 billion

#2

Headquarters: New York, New York
2017 prescription sales: \$45.4 billion
Projected 2024 sales: \$51.2 billion

#3

Headquarters: Basel, Switzerland
2017 prescription sales: \$41.7 billion
Projected 2024 sales: \$50.6 billion

#4

Headquarters: New Brunswick, New Jersey
2017 prescription sales: \$34.4 billion
Projected 2024 sales: \$47.7 billion

#5

Headquarters: Paris, France
2017 prescription sales: \$34.1 billion
Projected 2024 sales: \$47.4 billion

#6 GlaxoSmithKline

Headquarters: London, United Kingdom
2017 prescription sales: \$28.7 billion
Projected 2024 sales: \$38.4 billion

#7 MERCK

Headquarters: Kenilworth, New Jersey
2017 prescription sales: \$35.4 billion
Projected 2024 sales: \$38.0 billion

#8

Headquarters: North Chicago, Illinois
2017 prescription sales: \$27.7 billion
Projected 2024 sales: \$37.2 billion

#9 AstraZeneca

Headquarters: London, United Kingdom
2017 prescription sales: \$19.8 billion
Projected 2024 sales: \$31.7 billion

#10 Bristol-Myers Squibb

Headquarters: New York, New York
2017 prescription sales: \$19.3 billion
Projected 2024 sales: \$28.7 billion

Adapted from <https://www.fiercepharma.com/special-report/top-10-drugmakers-2024>